When should liver function tests (LFTs) be repeated in a patient receiving isoniazid (INH) 300 mg daily?

LFT Monitoring for INH 300 mg

For patients with normal baseline liver function and no risk factors, routine LFT monitoring is not required—only repeat LFTs if symptoms of hepatotoxicity develop (fever, malaise, vomiting, jaundice, or unexplained deterioration). 1, 2

Risk-Stratified Approach to LFT Monitoring

Low-Risk Patients (No Routine Monitoring)

Patients with all of the following do NOT need scheduled LFT monitoring 1:

• Normal pre-treatment liver function
• No pre-existing liver disease
• Age <35 years
• No HIV infection
• Not pregnant or postpartum (within 3 months of delivery)
• No regular alcohol use
• Not taking other hepatotoxic medications

For these patients: Educate about hepatotoxicity symptoms and instruct to stop medication immediately if symptoms occur. Perform LFTs only if symptomatic. 2

High-Risk Patients (Mandatory Regular Monitoring)

Monthly LFT monitoring is required for 2, 3:

• Age ≥35 years
• HIV infection
• Pregnant women or postpartum period (within 3 months)
• Chronic liver disease (hepatitis B/C, cirrhosis, alcoholic hepatitis)
• Regular alcohol consumption
• History of injection drug use
• Women from minority groups (particularly Black and Hispanic)
• Concurrent hepatotoxic medications

For patients with chronic liver disease specifically: Monitor weekly for 2 weeks, then every 2 weeks for the first 2 months, then monthly thereafter. 1

Patients with Abnormal Baseline LFTs

If AST/ALT ≥2× upper limit of normal (ULN):

• Monitor weekly for 2 weeks, then every 2 weeks until normalized 1

If AST/ALT <2× ULN:

• Repeat at 2 weeks
• If decreased: monitor only for symptoms
• If increased to ≥2× ULN: follow protocol above 1

Critical Thresholds for Action

Stop INH immediately if: 1, 2

• AST/ALT ≥5× ULN (asymptomatic patients)
• AST/ALT ≥3× ULN with symptoms
• Any elevation of bilirubin
• Symptoms of hepatitis (fever, malaise, vomiting, jaundice, dark urine, right upper quadrant pain)

FDA Label Guidance

The FDA label emphasizes that for persons 35 and older, hepatic enzymes (AST and ALT) should be measured prior to starting isoniazid therapy and periodically throughout treatment 4. The label also states that liver function tests are not a substitute for monthly clinical evaluations and patients must be instructed to immediately report hepatotoxicity symptoms. 4

Common Pitfalls to Avoid

1. Over-monitoring low-risk patients: This increases costs without improving outcomes and may lead to unnecessary treatment interruptions for transient, asymptomatic transaminase elevations 1, 5

2. Under-monitoring high-risk groups: The FDA boxed warning specifically highlights increased risk in women (particularly minorities) and postpartum patients—these groups warrant closer surveillance 4

3. Relying solely on LFTs without clinical assessment: Monthly symptom review is mandatory for all patients regardless of whether LFTs are being monitored 2

4. Continuing therapy with symptomatic transaminase elevation: Even modest elevations (3× ULN) with symptoms warrant drug discontinuation 2

Evidence Nuances

The British Thoracic Society guidelines 1 and American Thoracic Society recommendations 2 are concordant on the risk-stratified approach. Research evidence 6, 7 demonstrates that hepatotoxicity typically occurs within the first 3 months of treatment, with one study showing mean onset at 3 weeks 7. The FDA label 4 notes that isoniazid-associated hepatitis usually occurs during the first 3 months, supporting more intensive early monitoring in high-risk patients.

While some research suggests more frequent monitoring even in low-risk patients 6, the guideline consensus prioritizes symptom-based surveillance for those without risk factors to balance safety with practicality 1, 2.